|
1）United Network for organ sharing.http://www.unos.org/（2012.7.1確認）
|
|
|
|
|
2）Muzaale AD, Dagher NN, Montgomery RA, et al. Estimates of early death, acute liver failure, and long-term mortality among live liver donors. Gastroenterology. 2012; 142: 273-80
|
|
|
|
|
|
3）Eurotransplant. International foundation.http://www.eurotransplant.org/cms/index.php?page=annual_reports (2012.7.1確認)
|
|
|
|
|
|
4）日本肝移植研究会．肝移植症例登録報告．移植．2011; 46: 524-36
|
|
|
|
|
5）日本臓器移植ネットワーク・ホームページ.http://www.jotnw.or.jp（2012.7.1確認）
|
|
|
|
|
|
6）Monbaliu D, Pirenne J, Talbot D. Liver transplantation using donation after cardiac death donors. J Hepatol. 2012; 56: 474-85
|
|
|
|
|
7）Foley DP, Fernandez LA, Leverson G, et al. Biliary complications after liver transplantation from donation after cardiac death donors: an analysis of risk factors and long-term outcomes from a single center. Ann Surg. 2011; 253: 817-25
|
|
|
|
|
|
8）Taner CB, Bulatao IG, Keaveny AP, et al. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus. Liver Transpl. 2011; 17: 641-9
|
|
|
|
|
|
9）Hernandez-Alejandro R, Croome KP, Quan D, et al. Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts. Transplantation. 2011; 92: 686-9
|
|
|
|
|
|
10）Cholongitas E, Goulis J, Akriviadis E, et al. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis B virus recurrence after liver transplantation: a systematic review. Liver Transpl. 2011; 17: 1176-90
|
|
|
|
|
|
11）Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastro-enterology. 2011; 141: 1212-9
|
|
|
|
|
|
12）Bitetto D, Fabris C, Falleti E, et al. Recipient interleukin-28B Rs12979860 C/T polymorphism and acute cellular rejection after liver transplantation: role of the calcineurin inhibitor used. Transplantation. 2012; 93: 1038-44
|
|
|
|
|
|
13）Graziadei IW, Zolle HM, Schloegl A, et al. Early viral load and recipient interleukin-28B rs12979860 genotype are predictors of the progression of hepatitis C after liver trans-plantation. Liver Transpl. 2012; 18: 671-9
|
|
|
|
|
|
14）Eurich D, Boas-Knoop S, Bahra M, et al. Role of IL28B polymorphism in the development of hepatitis C virsus-induced hepatocellular carcinoma, graft fibrosis, and posttransplant antiviral therapy. Transplantation. 2012; 93: 644-9
|
|
|
|
|
|
15）DAmico F, Schwartz M, Vitale A, et al. Predicting recurrence after liver transplantation in patients with hepatocellular carcinoma exceeding the up-to-seven criteria. Liver Transpl. 2009; 15: 1278-87
|
|
|
|
|
|
16）Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007; 25: 310-2
|
|
|
|
|
|
17）Mazzaferro V, Bhoori S, Sposito c, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl. 2011; 17: S44-S57
|
|
|
|
|
|
18）Mailey B, Artinyan A, Khalili J, et al. Evaluation of absolute serum α-Fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg. 2011; 146: 26-33
|
|
|
|
|
|
19）Todo S, Furukawa H, Tada M, et al. Extending indication: Role of living donor liver trans-plantation for hepatocellular carcinoma. Liver Transpl. 2007; 13: S48-S54
|
|
|
|
|
|
20）Fujiki M, Takada Y, Ogura Y, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transpl. 2009; 9: 2362-71
|
|
|
|
|
|
21）Taketomi A, Sanefuji K, Soejima Y, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carci-noma after living donor liver transplantation. Transplantation. 2009; 87: 531-7
|
|
|
|
|
|
22）Piardi T, Gheza F, Ellero B, et al. Number and tumor size are not sufficient criteria to select patients for liver transplantation for hepato-cellular carcinoma. Ann Surg Oncol. 2012; 19; 2020-6
|
|
|
|
|
|
23）Bertuzzo VR, Cescon M, Ravaioli M, et al. Analysis of factors affecting recurrence of hepato-cellular carcinoma after liver transplantation with a special focus on inflammation markers. Transplantation. 2011; 15: 1279-85
|
|
|
|
|
|
24）Yamada T, Tanaka K, Uryuhara K, et al. Selective hemi-portocaval shunt based on portal vein pressure for small-for-size graft in adult living donor liver transplantation. Am J Transpl. 2008; 8: 847-53
|
|
|
|
|
|
25）Ogura Y, Hori T, EI Moghazy WM, et al. Portal pressure < 15 mm Hg is a key for successful adult living donor liver transplantation utilizing smaller grafts than before. Liver Transpl. 2010; 16: 718-28
|
|
|
|
|
|
26）Botha JF, Langnas AN, Campos BD, et al. Left lobe adult-to-adult living donor liver trans-plantation: small grafts and hemiportocaval shunts in the prevention of small-for-size syndrome. Liver Transpl. 2010; 16: 649-57
|
|
|
|
|
|
27）Ishizaki Y, Kawasaki S, Sugo H, et al. Left lobe adult-to-adult living donor liver transplantation: Should portal inflow modulation be added? Liver Transpl. 2012; 18: 305-14
|
|
|
|
|